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ABSTRACT
Background: Levodopa is the most commonly used medication to improve motor
sequelae in persons with PD (PwPD). However, levodopa and dietary protein compete for
absorption in the gut and blood brain barrier. Dietary proteins are essential for growth
and physical functioning, which generally deteriorate with PD progression. Informal
caregivers (ICG) often assist PwPD with meal and medication management, but have
reported information deficits regarding dietary and medication management for PwPD.
Objective: To obtain qualitative information related to dietary knowledge and attitudes,
and quantitative data on dietary behaviors from PwPD and their ICG.
Methods: Cross-sectional, mixed-methods study. A semi-structured interview was used
to collect qualitative data. Quantitative data was collected through use of, two 24-hour
dietary recalls and the Dietary Screening Tool.
Results: Ten dyads completed this study. All PwPD were found to be at possible
nutrition risk, and consume an average protein intake above recommended values. The
dyads reported misinformation, and limited knowledge surrounding medication and meal
management. Emerging qualitative themes included Reliance on Caregiver for Buying
and Preparing meals, Reduced Enjoyment of Foods and Meal Times, Barriers to Dietary
Intake, Lack of Nutrition Knowledge, Barriers to Medication Management, Management
of Symptoms, and, Access to Medication Information
Conclusion: There is a lack of nutrition and medication knowledge, and a need for more
awareness of the protein-levodopa interaction and strategies to attenuate the fluctuations
that may occur within the dyads. Interdisciplinary teams for PwPD could help to improve
health and delay progression of PD if followed early in diagnosis.
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PREFACE
This thesis was written to comply with the University of Rhode Island graduate
school Manuscript Thesis Format. This thesis contains one manuscript: Knowledge,
Attitudes and Behaviors to Dietary Management in Parkinson’s disease. This manuscript
has been written in a form suitable for publication in Disability and Health Journal.
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ABSTRACT
Background: Levodopa is the most commonly used medication to improve motor
sequelae in persons with PD (PwPD). However, levodopa and dietary protein compete for
absorption in the gut and blood brain barrier. Dietary proteins are essential for growth
and physical functioning, which generally deteriorate with PD progression. Informal
caregivers (ICG) often assist PwPD with meal and medication management, but have
reported information deficits regarding dietary and medication management for PwPD.
Objective: To obtain qualitative information related to dietary knowledge and attitudes,
and quantitative data on dietary behaviors from PwPD and their ICG.
Methods: Cross-sectional, mixed-methods study. A semi-structured interview was used
to collect qualitative data. Quantitative data was collected through use of, two 24-hour
dietary recalls and the Dietary Screening Tool.
Results: Ten dyads completed this study. All PwPD were found to be at possible
nutrition risk, and consume an average protein intake above recommended values. The
dyads reported misinformation, and limited knowledge surrounding medication and meal
management. Emerging qualitative themes included Reliance on Caregiver for Buying
and Preparing meals, Reduced Enjoyment of Foods and Meal Times, Barriers to Dietary
Intake, Range of Nutrition Knowledge, Barriers to Medication Management,
Management of Symptoms, and, Access to Medication Information
Conclusion: There is a lack of nutrition and medication knowledge, and a need for more
awareness of the protein-levodopa interaction and strategies to attenuate the fluctuations
that may occur within the dyads. Interdisciplinary teams for PwPD could help to improve
health and delay progression of PD if followed early in diagnosis.
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INTRODUCTION
Parkinson’s disease (PD) is a progressive neurodegenerative movement disorder
that currently affects over 900,000 Americans, and is expected to double by 2030 1-3.
While the etiology of PD is not well understood, it involves death of dopamine producing
neurons in the substantia nigra, resulting in loss of sensorimotor control, balance, gait,
mood, cognition, communication and swallowing1, 4-6. These PD sequelae (consequences
of pre-existing conditions) lead to time-intensive and expensive management strategies
including visits to health professionals, medications, surgeries, and complementary health
approaches ranging from $10-14 thousand dollars per person annually7. In addition to
public health costs, there are also costs on the informal caregivers (ICG) who spend 39+
hours a week on management for people with Parkinson’s disease (PwPD)8.
Levodopa is the most common dopaminergic medication used to improve motor
function, quality of life, and reduce morbidity and mortality in PwPD9. However,
consumption of dietary protein and levodopa compete for absorption at the gut and blood
brain barrier9, 10. Dietary proteins are essential as they promote muscle mass retention,
growth, and physical functioning2. Previous research shows that PwPD consume more
protein then recommended (0.8g/kg), and a higher protein intake is associated with a
higher daily levodopa dose over time10. This relationship may be partially attributed to
protein-levodopa interaction (PLI), leading to higher doses of levodopa which can be
ineffective in reducing motor sequelae10, 11. Therefore, it is recommended that levodopa
be consumed between 30-120 minutes before or after a protein food5, 12, 13. In addition to
medication timing, a low-protein diet (LPD) or protein redistributed diet (PRD) diet have
been recommended to minimize the PLI and reduce motor fluctuations in PwPD14, 15. A
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LPD restricts total daily protein intake to 0.5g/kg/day14, while a PRD limits protein intake
to 7-15g before the dinner meal with a goal protein intake of 0.8g/kg/day10, 14, 16-18.
However, there are inconsistent recommendations for PwPD and their ICG on how to
adequately manage this food-drug interaction14, 16, 19.
Informal caregivers (unpaid family member or friend) 20-22 often assist PwPD with
many care issues including meal and medication management, which become more
complex as the disease progresses22, 23. Medication management is a “high-level”,
medically related task, in the caregiver literature22, and ICG have reported information
deficits regarding dietary and medication management for PwPD, all contributing to the
feelings of stress surrounding caretaking19, 22-29. Therefore, the purpose of this study was
to obtain qualitative information related to dietary knowledge and attitudes, and
quantitative data on dietary behaviors from PwPD and their ICG. It was hypothesized that
PwPD and their ICG will report limited knowledge, and/or misinformation but a positive
attitude towards education in regards to dietary management. Also, PwPD will be at
increased nutritional risk and not adhere the nutrient intake recommendations. This data
will provide insight to what PwPD and their ICG believe about diet and levodopa
management for healthcare professionals.
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METHODS
Participant Recruitment
The current cross-sectional, mixed-methods study was conducted from October
2017 to January 2018. People with PD and their ICG were recruited as dyads from PD
health clinics and rehabilitation centers throughout Rhode Island. All participants were
community-dwelling adults aged 18 and older, who had access to a telephone. The PwPD
self-reported their disease stage based on the Hohn-Yahr (HY) scale (stages 1-4)30 and
reported adherence to taking at least one levodopa-containing medication. Participants
with PD were excluded if they received calories from enteral/parenteral nutrition, or
scored ≤18 on the Telephone Montreal Cognitive Assessment (T-MoCA). This study was
approved by the University of Rhode Island Institutional Review Board.
Data Collection
Data were collected during 3 assessments, which included two-telephone calls
and one home visit. The first assessment was a screening phone call to review inclusion
criteria, administer the T-MoCA, and complete the informed consent process.
Assessment #2 was a second telephone call where the dietary screening tool (DST), and
the first 24-hour dietary recall (24HR) were completed. For the DST, a total score from
0-105 was calculated and categorized with one of three nutritional risk levels; (<60) at
risk, (60-75) possible risk, and (>75) not at risk31. The Nutrition Data System for
Research was used to collect 24HR data by use of the multiple-pass interview approach
and, distribution of the foods amount booklet for adequate recall32. Assessment #3 was a
home visit to the dyad, where anthropometric assessments (height, weight and calculated
BMI), a past medical history questionnaire, the second 24HR, and a 21-question semi-
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structured interview were completed.
Moderator Guide
Semi-structured interview questions were created by the research team to explore
3 domains, 1) Eating Environment, 2) Dietary Intake and, 3) Medication Management
(Table 1). Questions were piloted with 3 PD dyads with similar inclusion criteria to
determine content validity and understandability of the interview. All interviews were
audio-recorded, transcribed verbatim and coded using thematic qualitative content
analysis33. Structural coding, using questions and key phrases from the moderator guide
was used to categorize the data into codes, then the codes were systematically reviewed.
The primary author and an undergraduate researcher reviewed and coded the transcripts
separately, then discussed their findings to identify the most common themes, and
generated the final themes together. Qualitative content was summarized and direct
quotes were used to illustrate the perspectives of the participants (Table 2). Participants
with PD and their ICG are identified in the text as “PD”, or “ICG”, followed by a number
that was assigned sequentially as surveys were completed.
Data Analysis
Descriptive statistics and data from the questionnaires and 24HR were analyzed
using SPSS Version 25 (IBM Corp, New York). Normality was assessed using skewness
and kurtosis. Categorical variables are reported as numbers and percentages, and
continuous variables are reported as mean ± standard deviation. All data collected from
the moderator guide was analyzed using NVivo 11 QSR (International Pty Ltd, Victoria
Australia).
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RESULTS
Demographics
Ten PwPD and their ICG participated in this study. Table 3 displays all
demographic data. Mean ages of the participants were, 68.7±8.5 years (range 50-82
years) for the PwPD, and 69.4±5.6 years (range 57-78 years) for ICG. Seventy percent of
the PwPD and, 30% of were ICG were males. All of the PwPD and 90% of the ICG were
retired. All of the PwPD and 60% of the ICG had at least an associates degree. PwPD had
been diagnosed with PD for 11.4±4.9 years (range of 8-19 years) and had been taking
levodopa for 6.9±3.84 years (range 2-15 years). Mean scores on the T-MoCA was
20.30±1.56. The qualitative results are presented according to the moderator guide
domains. Additional themes are incorporated within each of those domains.
Dietary Intakes
This domain covered knowledge of recommended dietary intakes and attitudes
about food and nutrition since the diagnosis of PD. Two emerging themes came from this
domain (Table 2a). In the Barriers to Dietary Intake theme, all of the participants
explained some barriers related to PD sequelae that has affected dietary intake. The ICG
explained digestive issues that pose as a barrier to the types of foods that they buy and
prepare. Another barrier was the modifications of foods. Many participants reported no
difficulty with chewing and swallowing but, when asked what kind of dietary changes
they have made since being diagnosed with PD, the answers related to changes due to
swallowing difficulties that have affected the foods they consume. Other participants
described how the motor sequelae as a result of PD act as a barrier because they impact
the way they get the foods into their mouths. Despite the barriers, a majority of the PwPD
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reported consuming a healthy diet, however they reported an inclusion of sweets due to
the decreased taste of foods, and sweet foods containing a stronger flavor.
The other emerging theme was, Range of Nutrition Knowledge for PD, where
many PwPD and their ICG reported some knowledge, but confusion about the PLI. Some
were not aware that dietary proteins compete with levodopa or, recently learned about
this interaction. The participants were also unaware of the PRD and LPD that may help
decrease some of the motor fluctuations they experience. Due to the range of knowledge
surrounding the protein altered diets, many participants spoke about the challenges that
they would have following these diets. Despite this range of nutrition-related knowledge
the majority of the participants reported that they would be very interested in learning
“anything you have” about the medication-meal management.
Eating Environment
This domain included two items, which addressed PwPD and their ICG attitudes
around food and some of the behaviors they exhibit during the mealtime process (Table
2b). In the Reliance on ICG for Buying and Preparing Meals theme, participants reported
that ICG play a large role in buying and preparing foods in the home. For approximately
half of the dyads, the PwPD helped plan what foods to buy but the ICG do most of the
purchasing and preparation, especially for foods requiring more advanced preparation.
Also, in the Reduced Enjoyment of Foods and Meal Times theme, both PwPD and ICG
described a decreased enjoyment in the eating experience and an avoidance of going out
to eat because of PD progression.
Medication Management
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This domain gave insight into self-reported behaviors around medication intake,
three themes emerged (Table 2c). The first theme, Barriers to Medication Management,
showed that in most of the participants, the responsibility of managing medication was on
the PwPD. However, many PwPD described challenges remembering to take the
medication at the right time due to busy schedules. Many used of devices and strategies
to help overcome their challenges to taking their medication but even those could result
in their own problems. Another theme that arose was, Management of Symptoms, despite
some barriers to taking the medication, when asked about how the medication manages
daily PD symptoms all of the participants discussed a positive effect if the medication
was working that day. Finally, the theme, Access to Medication Information, described
how the participants accessed medication information. A majority mentioned that they
would find information online or talk with their peers. Most described that they would
not feel comfortable contacting their doctor or a health care professional because they are
not readily accessible, and some of the information provided is not easily understood.
Although many participants had means of accessing medication information, most
recognized the importance of staying up-to-date with information and expressed positive
attitudes toward learning.
Dietary Data
In addition to the qualitative data about diet and medication management within
this population, dietary assessments were used to better understand results in relation to
the qualitative and quantitative data. Mean score on the DST was 66.4±13.9, which
categorizes this population at possible nutrition risk and further investigation found that
30% of PwPD were not at nutrition risk, 40% were at possible risk, and 30% were at
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nutrition risk. Mean BMI for the PwPD was 27.1±4.7 (overweight) with 30% classified
as normal weight, 50% as overweight and 20% obese. All dietary data is displayed in
Table 4. Participants consumed an average of 1955.7±678.2 calories, at 4.5±1.4 eating
times per day. Eighty percent of the PwPD consumed their medication and meals within
30 minutes of each other. Timing of meals and levodopa intakes are in Figure 1. Average
protein intake per kg of body weight was 0.9±0.2, the recommendation is 0.8g/kg/day,
and in this sample 30% were below and 70% were above this recommendation.
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DISCUSSION
The goal of this study was to explore the knowledge, attitudes, and behaviors of
dietary management in PwPD and their ICG through dyadic interviewing and dietary
assessments. The major findings of this study were the range of knowledge related to
food-medication management and, not adhering to protein recommendations for this
population. PwPD and their ICG have received little information related to the PLI and
were confused about meal and medication timing, which is consistent with a qualitative
dyadic study by Shin et al19, that revealed participants feeling stress and uncertainty
related to medication and diet management19. In addition to the qualitative data found,
dietary intake information confirmed the lack of adherence to protein-levodopa timing.
Participants took their medications less than the 30-120 minutes recommended prior to
consuming a meal (80%), and more protein than the RDA (0.9g/kg), with more grams of
protein during the day than at night. These findings are also consistent with a previous
PD dietary studies which found that, 75% of PwPD consumed protein with their levodopa
and more protein during the daytime10, 34.
Levodopa is the most effective medication to control PD motor sequelae9,
therefore it is important to identify possible interactions and barriers to compliance so
PwPD can receive the greatest symptomatic benefits. All of the participants reported
difficulties talking to their healthcare providers about medication and most resorted to the
internet or peers, which may not provide valid information. Registered dietitians (RDs)
are trained in managing food-drug interactions and can help provide reliable information
to PwPD and ICG. However, RD’s are often excluded from the management of PD.
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Therefore, future research should further investigate the use of RDs in the management of
PD, and ways to increase access to PD health information.
The PwPD in this sample were responsible for managing their own medication,
which is inconsistent with previous research which indicated that ICG are highly
involved in medication management22. This could be attributed to the study participants
being highly educated and screened for cognitive impairments. Regardless, the PwPD
reported that levodopa has positive effects on their motor sequelae when it is “working”.
Due to the reported range of knowledge about the PLI and the medication fluctuations,
PwPD may benefit from a LPD or PRD as both have been effective in reducing motor
fluctuations and total levodopa dosag17, 18.
The ICG took on the majority of the food purchasing and preparation in this
sample, which is consistent with previous literature, where ICG have been found to
become the primary food provider when food and food-related work become a problem35.
The PwPD experienced decreased enjoyment around food and the eating environment
which can be contributed to PD sequelae like, decreased taste, gastrointestinal (GI)
distress, taste and motor flucutations. Person’s with PD described a loss of taste that
affected their enjoyment of foods; previous research has shown a decreased desire for
most foods, except for those with strong tastes, such as ice cream36. In addition to taste,
GI distress decreased eating enjoyment due to decreased gastric emptying rate which will
increase abdominal distention, discomfort, nausea and early satiety and bloating in
PwPD5.
Other sequelae that decreased food enjoyments included, chewing and swallowing
and motor functioning. Previous research has found that the prevalence of dysphagia in
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PwPD varies (35-80%) due to the majority of PwPD self-reporting no swallowing
difficulties, but showing evidence on a bedside swallowing test37. While this study did
not directly assess swallow function, symptoms associated with dysphagia were
identified and affected the foods participants consumed. Additionally, the reported
difficulties in using utensils while eating show the need for an occupational therapist
(OT) however, only 13-25% of PwPD have utilized OT services because most patients
are not referred to their services until the later stages of the disease, when it may already
be too late38. Therefore, the inclusion of a multidisciplinary team of RDs, SLPs and OTs
early in PD diagnosis could allow PwPD to maintain more activities of daily living as the
disease progresses and deter some of these barriers to dietary intake.
The second aim was to identify the nutritional risk status and dietary intakes of
PwPD through two dietary assessments. Optimal nutritional status is difficult for PwPD
to maintain due to cognitive decline, gastrointestinal issues, difficulty swallowing, and
PLI1, 5, 6. In the current sample, PwPD were found to be at possible nutrition risk, which is
consistent with previous research39. Table 5 compares DST and NDSR data to show
quality and variety of the participants diets. While there are no formal dietary guidelines
for PwPD our findings show participants are not meeting the general recommendations
for the Dietary Guidelines for Americans (DGAs), or those that are specific for PwPD5,40.
While this population was meeting the recommendations for macronutrient and calorie
intakes, on average they did not meet the 30-35g recommendation of fiber per day to
alleviate constipation5, or the vitamin D, calcium, magnesium and potassium
recommendations for muscle and bone health40. Meeting the recommendations for all
nutrients is important to improvement in nutritional status and slow disease progression5.
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The large standard deviations of the results, exhibit the heterogeneity of PwPD which
makes standardized intakes difficult to quantify, therefore all dietary recommendations
should be individualized to fit the needs of PwPD 40. The DGAs may be utilized early in
the diagnosis but once levodopa therapy is introduced, protein intake may need to be
altered so the medication absorption can be improved5. Additionally, when educating
PwPD, health professionals should be aware of cognitive deficits when presenting
information to PwPD and should present information multiple times and provided written
materials.
In the current study, PwPD and their ICG showed a range of knowledge, and
misinformation about dietary recommendations for PwPD but showed a positive attitude
towards receiving education in regards to managing dietary protein intake and levodopa.
Also, this population’s dietary behaviors showed them to be at possible nutrition risk and
consuming more than the RDA for protein, which may call for future dietary research to
explore diet quality and variety in PwPD. However, due to the small, homogenous
sample size this information cannot be generalized to a larger population of PD.
Additionally, this sample included mostly white and highly educated participants which
is common in the PD literature, future research should focus on targeting other races and
education levels. Also, due to the cross-sectional, descriptive design of the study, only
one-time point was obtained and more longitudinal approaches should be considered for
this population. All of the dietary data is based on self-reports which may affect the
accuracy, but in order to increase some validity, food amount booklets were sent to all
participants and referred to, and the multiple pass methods was utilized during the 24HR.
However, despite these limitations, this study is unique because it included both PwPD
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and their ICG to gather mixed methods data which will be beneficial for interdisciplinary
teams working with this population. This research could be modified to attenuate to
additional neurological disorders which affect 1 in 7 households 3.
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CONCLUSION
Current findings confirm lack of nutrition and medication knowledge and the
need for nutrition education around food-drug interaction and managing disease
sequelae’s impact on dietary intake. Overall, the results of the study identify areas for
education that have the potential to attenuate motor fluctuations secondary to medication
intake and maximize management of disease symptoms overtime. Future research should
focus on interdisciplinary teams for PwPD could help to improve health and delay
progression of PD if followed early in diagnosis.
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TABLES AND FIGURES
Table 1: Qualitative Domains
Eating
1. Describe the most challenging aspects of preparing and eating
Environment:
meals since the diagnosis of PD
2. Who is responsible for buying and preparing food in your home?
Dietary Intake:
1. How has your diet changed since being diagnosed with PD?
Prompt: are there any foods that you have stopped or increased
eating due to your diagnosis?
2. How would you describe your current diet?
3. Who have you spoken with about your diet and what have they told
you?
4. Is there anything you would like to know about the foods that you
eat or your daily nutrition in general? Prompt: what questions or
concerns do you have about your daily eating or about the foods you
eat in general?
5. What is your understanding of a PRD or LPD? Prompt: the PRD
limits protein during the day and includes more protein at dinner,
the LPD limits all protein during the day and at dinner
6. What challenges would you anticipate if you were following a PRD
or LPD?
7. What difficulties do you have chewing or swallowing your food or
beverages? Prompt: what fluids do you have difficulties consuming?
How often do you cough during meals? How much more time does it
take you to eat than before the diagnosis?
8. Do you modify the textures or consistencies of your foods or
beverages? Prompt: Do you consume ground meat instead of whole
pieces? Do you soften or puree your vegetables? Do you use
products like “Simply Thick” to thicken the fluids you consume?
Medication
1. Describe your greatest challenges to taking your levodopa
Management:
medication as prescribed by your doctor?
2. How you do cope or overcome the challenges to taking your
levodopa medication as prescribed by your doctor?
3. What is your daily levodopa schedule?
4. What information have your doctor and/or pharmacist provided
bout the timing of your medication?
5. How do you time your food and medication intakes?
6. How do you obtain information about your levodopa medication?
7. How well does levodopa manage your daily symptoms? Prompt: do
you ever feel shaky, unsteady or sluggish after consuming your
medication?
8. What do you know about the food-drug interaction between
levodopa and protein?
9. What information would you like to know about your medication
management? Prompt: how interested are you in learning more?
10. Do you rely on your caregiver to receive your levodopa medication?
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Table 2: Qualitative Themes
a. Dietary Intake
-Barriers to Dietary
Intake

“It’s a Mediterranean diet with cookies and stuff like that.” –
PD8
“We eat a lot of fish and chicken, occasionally red meat and
my worse thing is cookies, and chips occasionally.” –PD9
“My taste has gotten worse over the years, I think I eat foods
by the memory of what they taste like.” –PD3
“I have noticed some foods don’t have as much taste, (my
doctor) said it’s understandable that I like to eat chocolate
because it has a strong flavor.” –PD2
“There are some digestive concerns every once in a while.
Sometimes spaghetti and meatballs can make his stomach a
little acidic so I have to be careful about what we eat and how
it will affect him.” –ICG1
“(He stopped eating) anything tomato because he has that
burning tongue syndrome.” -CG3
“I like to eat salads but I am concerned because once I did
have choking.” –PD1
“I’m more conscious in how I eat food, I cut smaller pieces,
especially meat or something, lettuce or salad I cut into small
pieces.” -PD1
“Certain kinds of lettuce seem to be harder, mostly what I use
is the heart of romaine, tomatoes, cucumbers, things you can
feel going down. I think I was putting spinach in a salad,
trying to use that, and the spinach became a choking hazard. I
had already also put spinach in meatloaf and he said I can’t
swallow parts that have spinach, so I don’t anymore.” –ICG1
“I’ve had trouble consuming fluids… water or juice, but very
rarely, it’s not a problem.” –PD1
“Sometimes I choke on water of coffee, so I take smaller
sips.” –PD5
“I don’t have a lot of difficulty except a couple of times I was
eating autumn soup and I aspirated a little on the soup and
choked really bad.” –PD6
“I initially had trouble with things like crackers and pretzels
so I stopped eating those really dry things. I’ve reintroduced a
lot of that overtime just being more mindful and having liquid
nearby.” –(PD8)
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“I don’t modify the textures, if there is something like steak
or a pork chop I cut it up into much smaller pieces than he
used to have.” –ICG4
“Sometimes when you drink water, something that’s very
crumbly, he will have difficulty, start coughing, so he has to
drink water after it. And every once in a while, when he
swallows water or diet coke or something he’ll cough, but not
very often.” –ICG4
“Sometimes water tends to go down the wrong hole. I cough
on occasion, now and then.” –PD3
-Range of Nutrition
Knowledge for PD

“I stay away from beef because it’s too difficult to slice it
sometimes…” –PD3
“Using utensils, like gripping them and getting food into my
mouth without it falling in my lap. I take smaller bites and it
takes me longer to eat” –PD5
“I went through a period of difficulty getting it (food) into my
mouth but that was before the dosage of carbidopa/levodopa
that I’m taking now.” –PD6
“I have seen (diet information) online, I read things from the
APDA, I saw that mentioned once that it may be some help in
the absorption of the dopamine but I don’t recall it being
something that they necessarily were recommending it just
was sort of mentioned” –ICG1
“I am interested in trying to time the medication and the
protein consumption to see it we could make it happen that
the sinemet goes in a half-hour before the meal is consumed
and see is that makes a difference or does it have to be an
hour before or two hours after. I would be very interested in
knowing those things –ICG1
“I didn’t know and I don’t know how bad it is and I still don’t
know how long I should wait when I eat” –PD6
“The doctors don’t give you information about anything” –
PD8
“I get concerned when I take my Sinemet pill, is that
supposed to compete for absorption with fats and so it’s best
if you don’t take it with a heavy mean anyway but it also
makes you nauseous that’s why I start with crackers in the
morning.” –PD2

24

“I know that too much protein slows down the carbidopa but
other than that no. I never really experienced that though, I
know about it.” –PD5
“I was never told anything, until recently about protein being
a hindrance to absorbing dopamine, so I’ve been a little
concerned about when I am eating meals and when I am
taking medications, should I be waiting a half hour or should
I be waiting an hour? This is one issue I’ve been worrying
about.” –PD6
“Well the question that I have and have always had, and
people always give me answers but they’re not really answers
is the interaction between protein and Sinemet,
carbidopa/levodopa is confusing and really challenging
because 99% of the food that I eat has protein in it and some
sources say that even a trace amount of protein can interfere
with the carbidopa/levodopa. That is the only medication that
is having an effect on my brain and helps me be in more
control.” –PD8
“My understanding is that any amount of protein in the body
at the same time that carbidopa/levodopa is in the body
prevents is from entering the brain, it’s just a block- no
sinemet allowed here.” –PD8
“Because he actually requires more protein now, he has the
protein supplement, because of the energy level, because of
the PD, muscle support for sure, so a low protein diet would
be something that I am not keen on.” –ICG1
“I think he would get tired and be rather listless and the other
part would be trying to figure out having low protein during
the day and then why at night? He’s not going to do anything
then, that’s when we settle down. I’d rather say high protein
in the morning and decrease it during the day but even that
makes the meals off balanced.” –ICG1
“Yeah, I think it would be challenging. You’d have to start
and think about when you took your pills, when you ate, how
much protein you could have, so yes it would be
challenging.” –ICG4
“That I’m getting enough protein –PD5
“I don’t want my wife to have to make two meals. I’ll eat
whatever she eats so that would be a challenge.” –PD6
“It would be really challenging for me because I like to eat
small amounts of food a lot.” -PD8
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b. Eating
Environment
-Reliance on ICG
Buying & Preparing
Foods

-Reduced Enjoyment
of Foods & Meal
Times

“She’s taken over. Yeah, I used to do it all, I used to do a
quite a bit of cooking too.” –PD3
“He doesn’t prepare the meals, he can throw together a
sandwich if he needs to but I’m the cook.” –ICG1
“I used to like to experience and enjoy many foods of
different kinds (of food), now most foods don’t have much of
a taste and I also have to force myself to eat to put weight
on.” –PD1
“He doesn’t have his taste buds as good as they were so he
doesn’t enjoy a lot of stuff. I would say the things he enjoys
the most is probably sweets.” –ICG3
“We don’t go out to restaurants anymore because it’s too
much of a hassle.” –ICG5
“I am just not interested (in eating) anymore.” –PD11

c. Medication
Management
-Barriers to
Medication
Management

“Frequently what we have is a therapy sometime like today
when we came home it was about 12:15 and he was hungry, I
was starving so we had lunch right away, but he was due for a
pill at 12 so he had the pill, he ate lunch within that half hour
before it would have been fully absorbed.” –ICG1
“When you’re retired your day ought to be empty but ours
winds up having a lot of going to the YMCA for exercise
classes and Doctors visits and I wind up in a position where I
pretty much have to take the pill very close to a meal or put it
off longer than is appropriate.” -PD 2
“My greatest challenge, taking it on time –PD11. Taking it on
time and taking it throughout the day, you stop when you
know you’re not doing anything so –CG11. Yeah like if I’m
home, I tend not to take it –PD11. I try to remind her because
I see the signs when she runs out –CG11. Yeah like it bothers
him more than it bothers me, I don’t mind being off my meds,
I just move slower, but he says my face looks different and I
just move differently –PD11.
“I use an alarm in my phone to remind me when to take the
1:00pm and 6:00pm pills. It’s not uncommon for me to be in
a seminar when it would have gone off, and I’ve got my
phone turned off and I forget to take it until later.” -PD2
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“I had a cell phone all set up but he won’t carry a cell phone
so that has been a real problem, I am trying to come up with
an apparatus that he will use and carry.” -CG 4

-Management of
Symptoms

“I have pill box that I have in the drawer that has my vitamins
in it too, but then for lunch I would forget to take it if it
wasn’t out.” -PD 7
“We try writing down each time I take a dosage. So, if I take
carbidopa-levodopa every 4 hours, 4 times a day, if I start at
say 8am, I write 8am and know my next dose is due at 12
then 4. If I don’t write it down it’s like, did I take it at 7
yesterday because I was up earlier or did I sleep in and take it
at 9? - PD10.
“The impact of levodopa is pronounced it’s just a question of
how long it takes” –PD1
“I guess it controls some tremors, my jaw used to shake a lot
more visibly than it does now but it’s pretty successful” –PD2
“I think it helps a lot, I’d say maybe 50-60%.” –PD3
“There are days that I think I’m just as well off without pills,
but if I do that I realize that the pills really are doing some
good” –PD4
“If he takes them every four hours on time they make a huge
difference.” –ICG4
“If she misses a dose she will feel it if it goes past the four
hours.” –ICG5

-Access to Medication
Information

“When it’s working it works pretty well. I can walk without
any assistance, I walk with a can though because I have a
problem with my left hip. When I’m not doing well I will use
a walker and even that is a struggle” –PD6
“I couldn’t manage my life without it. I notice sometimes
feeling a little more sluggish or stuck, frozen is the term they
like to use so it’s really challenging to be at my best without
taking the medication.” –PD8
“If you have high protein, it just feels like you’re not
medicated –PD11
When (she’s) on the medication most people can’t even tell
she has Parkinson’s.” –CG11
“I would ask my doctor but he’s kind of hard to get a hold of
so we look it up.” –PD2
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“Absolutely none from the doctor, just how many times he
could take it but that’s all, not when” –ICG1
“Look online and the handouts you get at the pharmacy.” –
PD5
“I look online but the sheet comes with my medication, I get
2-3 pages of information and I scan it, I mean I read it when I
first got it but now I scan it in case there is something
different.” –PD7
“Online but probably more so on the information from the
pharmacy. You know how CVS sends 3-4 pages of stuff you
can’t understand, that I can’t understand. Usually that or
medical journals they have good information. And here at the
gym they post things that are pertinent, groups and surveys” –
PD10
“Well I’ve spoken about it with my peers in the support
groups and LOUD Crowd.” –PD8
“Online and talking to other people with Parkinson’s.” –PD11
“We’ll sit in the cafeteria when the guys are in LOUD, they’ll
talk about the down time, who has down time, who doesn’t. I
find a lot of information when I sit with the ladies -ICG3
“You just have to educate yourself and have a great support
group which we have at URI, we are so lucky. That is a
blessing that is worth so much and I think it’s a constant
battle but it’s also you have to keep educating yourself on all
the new stuff and it never lets up- ICG4
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Table 3: Participants Demographics
Age
Gender %(n)
Men
Women
Working Status %(n)
Working
Retired
Highest level of education %(n)
Some college
Associates degree
Bachelor’s degree
Master’s degree
Doctoral degree
Other health issues
Diabetes
Hypothyroidism
Hypertension
Heart condition
BMI %(n)
Normal
Overweight
Obese
Height (in)
Weight (kg)
Years since diagnosis
Years on levodopa
Levodopa dose/day (n)
T-MoCA
DST %(n)
Not at risk
At possible risk
At risk
Eating times/day (n)
Meals/day
Snacks/day
Protein intake (g/kg)
Protein pre-dinner (g)
Protein post-dinner (g)

PwPD
68.7±8.5

ICG
69.4±5.6

70(7)
30(3)

30(3)
70(7)

0(0)
100(10)

10(1)
90(9)

0(0)
10(1)
30(3)
30(3)
30(3)

40(4)
10(1)
40(4)
10(1)
0(0)

10(1)
10(1)
10(1)
20(2)
27.1±4.7
30(3)
50(5)
20(2)
67.2±3.0
78.9±16.5
11.4±4.9
6.9±3.8
3.9±1.0
20.3±1.6
66.4±13.9
30(3)
40(4)
30(3)
4.5±1.4
2.9±0.3
1.8±1.4
0.9±0.2
39.8±19.0
32.5±7.8
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Table 4: Nutrient Breakdowns

Calories
Total water (ml)
Carbohydrate (g)
Fiber (g)
Soluble
Insoluble
Fat (g)
Monounsaturated
Polyunsaturated
Protein (g)
Animal
Vegetable
Vitamin D (mcg)
Thiamine (mg)
Riboflavin (mg)
Niacin (mg)
Vitamin B6 (mg)
Vitamin B12 (mcg)
Folate (mcg)
Calcium (mg)
Iron (mg)
Magnesium (mg)
Potassium (mg)
Sodium (mg)

PwPD Intakes

Range

DGA Male

DGA Female

1955.6±678.2
1884.9±791.2
232.2±79.8
23.2±9.4
6.3±2.9
17.3±7.7
84.2±43.5 (38%)
32.3±20.2
17.8±9.6
72.3±20
44.2±12.3
17.8±9.6
377±296
1.6±0.5
1.9±0.6
21.3±6.8
1.8±0.7
4.2±2.5
415.1±186.9
839.6±410.3
14.8±8.2
324.5±179.5
2599.8±977.5
2544.5±715.2

905.5-3214
819.7-3372
98.7-308.6
6.5-29.7

2,000
3700
130
28

1,600
2700
130
22.4

24-179

20-35%

20-35%

43.6-106.3

56

46

28.9-1042
0.6-2
0.7-2.7
11.4-29.5
0.6-3.1
1.5-10.1
154.5-712.5
266-1066.5
5.7-33.1
132.5-762
1715-3540.5
1253.5-3493

600
1.2
1.3
16
1.7
2.4
400
1,000
8
420
4,700
2,300

600
1.1
1.1
14
1.5
2.4
400
1,200
8
320
4,700
2,300
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Table 5. Comparison of Dietary Groups between 2 Dietary Assessments
DST (points)
NDSR (servings)
Fruits
11.2 (15)
2.2 (2 cups)
Vegetables
11 (15)
3.7 (3 cups)
Whole Grains
10.4 (15)
1.7 (3.5oz.)
Lean Proteins
7.5 (10)
5.9 (6oz.)
Added Fats, Sugars & Sweets
11.9 (25)
5.8a
Dairy
4.5 (10)
1.3 (3 cups)
Processed Meats
7.5 (10)
0.7a
Supplements
50%
50%b
a

= There are no specific DGA recommendations for number of servings
= Percentage of participants using supplements

b
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Appendix A: Review of Literature
I.

Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that affects
over 900,000 Americans and by 2030 the prevalence is expected to double 1-3.
Parkinson’s disease causes motor and non-motor sequelae (consequences of preexisting conditions), such as resting tremors, slowness of movement, cognitive decline,
depression, sensory changes, difficulty swallowing, and gastrointestinal issues, all of
which can negatively impact dietary intake and nutritional status 1, 5-7. The motor
sequelae are commonly managed with levodopa therapy to improve motor function,
quality of life, and reduce morbidity and mortality in persons with PD (PwPD) 10.
Informal caregivers, those who provide the majority of care without monetary
compensation, assist PwPD in managing the disease sequelae and levodopa
medication23, 24. Additionally, caregivers are involved with all aspects of dietary
management such as menu planning and food purchasing and preparation, since PD
sequelae reduces the PwPD’s ability to complete these tasks24, 30. Dietary protein is
essential as it promotes muscle mass retention, growth, and physical functioning, which
generally deteriorate with PD progression1, 2, 11. However, dietary protein competes
with levodopa for absorption, therefore timing of levodopa and protein intake needs to
be managed properly11, 20. Dietary management is critical for PwPD as they are at
increased risk of poor nutritional status39, and need to minimize the protein-levodopa
interaction (PLI)17. Although dietary modifications exist for PLI management, PwPD
and their caregivers report misinformation regarding which dietary modifications are
optimal20. The purpose of this review is to investigate the sequelae associated with PD,
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and the treatments currently available to help PwPD and how their caregivers
contribute to a large amount of management of sequelae.
II.

Parkinson’s Disease
Parkinson’s disease is most prevalent in the fastest growing US population, adults

aged 65 and older3, and affects 1-2% of the population, globally4. The etiology of PD is
not well understood, but involves neuronal call death from the brain stem to the
cerebral cortex that result in loss of sensorimotor control, balance, gait, autonomic
function, mood, cognition, communication and swallowing1, 4-7. The disease often
presents with presents with the loss of dopamine-secreting neurons within the
sunstantia nigra and the presence of Lewy bodies 41. Therefore, there is a decrease in the
amount of dopamine, a neurotransmitter that regulates movement and emotional
response. When there is not enough dopamine present, non-motor and motor sequelae
will occur. Early signs of the disease include tremor, postural instability and
bradykinesias, which prompt a visit to the neurologist but, often go untreated as these
sequela are often attributed to the normal aging process4. The most common type of PD
is idiopathic, which presents in 90% of PwPD4, and often includes a young onset and,
akinetic and tremor predominance but each PwPD will present with their own set of
sequela. Due to the heterogeneity of PD, and the widespread pathology of PD the onset,
progression and etiology of most sequelae are not understood1.
Parkinson’s disease is often staged according to motor sequelae1, 31, by the five
stages of the Hoehn and Yahr (H&Y) scale with stage 5 being most advanced31. These
scores are assigned by the neurologist and can fluctuate as the disease progresses and
medications are altered. Scores are evaluated as the disease stage from 1, “unilateral
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disease”, 1.5 “unilateral plus axial involvement”, 2 “bilateral disease without
impairment of balance”, 2.5 “mild bilateral disease with recovery on pull test”, or, 3
“mild to moderate bilateral disease, some postural instability, physically independent”,
4 “severe disability, but still able to walk or stand unassisted”, and 5 “wheelchair-bound
or bedridden unless assisted”31. These stages will fluctuate with disease progression and
overall management of the disease, but give PwPD a guide as to where they stand in the
progression of their disease.
Management of PD is time-intensive and expensive management strategies
including doctors’ and other health professional appointments, medications, surgeries,
and complementary health approaches ranging from $10-14 thousand dollars per person
annually8. Due to the neurodegenerative nature of PD, a caregiver will be warranted to
take over all activities of daily living (ADLs) as the disease progresses 42.
Pharmacological management is the most frequently used management in PD, and
often presents with the most confusion and difficulties in compliance among PwPD and
their caregivers according to qualitative research23.
III.

Pharmacological Management of PD
The neurodegenerative, movement disordered mature of PD causes motor and

non-motor sequelae result in an increased burden on PwPD and their caregivers, which
effect physical, social, emotional and nutritional statuses 9. In order to uphold overall
quality of life, and slow progression of disease, there have been pharmacological
treatments studied and recommended to treat the sequelae41. Recommendations are based
on the individual due to the heterogeneity of PD41.
a. Motor Sequelae Management
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Medications used to treat the motor sequelae associated with PD act on the
neurological interactions in the striatum41. Recommendations are to initiate medication
when patients begin to experience functional impairment or social embarrassment from
their symptoms41. The choice of initial medication depends on the patient’s specific age
and what symptoms they are experiencing41. The three most typical medications used for
PwPD are 1) monoamide oxidase type B inhibitors (MAOBIs), 2) dopamine agonists and
3) levodopa41. These three produce dopaminergic effects; dopamine agonists and
levodopa work to bind to and activate dopamine receptors, while MAOBIs inhibit the
breakdown of dopamine. Additional drugs that may be used include beta-blockers,
anticholinergic and amantadine drugs41, which act to block postsynaptic receptors for
other neurotransmitters in the striatum, therefore making dopamine more available.
In the early stage of PD, when motor sequela are generally mild, MAOBIs,
anticholinergic, beta-blockers, or amantadine drugs are typically the first line of
treatment41. However, there has been inconclusive evidence on the overall effectiveness
of these drugs41. In a recent meta-analysis of MAOBIs in early PD, there was only a
small but significant symptomatic benefit shown with rasagilin43, 44. Anticholinergic
medications like, trihexyphenidyl, benztropine and procyclidine, have been shown to
improve some motor fluctuations compared to placebos in clinical trials but, have not
been shown to significantly help tremors44, 45. The beta-blocker, propanol is the most
effective when controlling tremors in PwPD44, 46-49. Additionally, The International
Parkinson and Movement Disorder Society recommends the use of amantadine’s,
unspecified for motor system management as mono- and adjunct therapy, despite the
mixed evidence supporting its treatment for PD44, 50. These drugs are known to be
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effective in the early stages of the disease but as motor sequelae become more
pronounced, or they are diagnosed earlier, stronger medications are warranted 41.
Dopamine agonists (carbidopa), and/or levodopa are typically prescribed as PD
progresses and motor sequelae become more prominent and activities of daily life are
impaired41. Dopamine agonists may be prescribed before levodopa in a more advanced
stage of PD, or as a first line of treatment if the patient is under 60 years of age.
Dopamine agonists result in less negative side effects than levodopa, and are typically
tried first in young on-set PD. However, dopamine agonists have been shown to cause
compulsive behaviors in PD, especially compulsive eating, which can result in
overweight and obesity and has a negative impact on health status 41. Therefore, it may
only be an effective treatment for a short time, before a full-levodopa treatment is
warranted.
Levodopa therapy has shown to provide the greatest symptomatic benefit for PD
including, less freezing gait, daytime drowsiness, edema, hallucinations and risk of
impulse control disorders. Levodopa is quickly metabolized in the plasma and has a short
half-life of 1.5 hours51, 52. Upon administration, levodopa crosses the blood-brain barrier
in order to be converted into dopamine, replacing the neurotransmitter deficient in PD.
Most PwPD start levodopa at 50mg one time per day, and then three to four times per day
equaling 100-200mg53. Levodopa is commonly combined with a dopamine agonist
(carbidopa) so there is an increase of levodopa in the central nervous system which will
improve one’s ability to tolerate the drug by reducing adverse side effects like nausea,
from peripheral decarboxylation51. There are several ways levodopa therapy can be
administered such as, immediate-, controlled and co-administration.
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Immediate-release (IR) medications combine carbidopa and levodopa to inhibit
metabolism in the periphery and allow an increase in central nervous system (CNS)
availability10. The IR formulas have short half-lives and therefore need to be taken more
frequently44, 52, 54, 55. Because of the increased frequency in taking IR formulas, overtime
there is a shortening of clinical response and higher, more frequent dosing to compensate
for the change in pharmacodynamics44, 52, 54, 55. These changes due to chronic levodopa
use, increases the probability of over and under dosages which lead to motor
complication. Motor sequelae have occurred as early as 5-6 months after levodopa
treatment56. After 2 years only 20% of patients experience sustained benefits 57, and after
5 years, 70% experience on-off fluctuations and dyskinesia’s58, 59. As time on IR
levodopa increases, wearing off becomes more frequent, levodopa doses need to be given
in increasing frequency.10
Controlled-release (CR) medications are degradable polymer matrices that slow
the release of levodopa into the gut10. These medications produce less “off” time and
more “on” time10. Although levodopa levels are more stable, the absorption of CR
levodopa is delayed, making symptom relief less predictable60. Research has shown that
in the long-term (5 years), there is no difference in degree of motor fluctuation and
dyskinesia’s between CR and IR medications in patients with moderate to severe motor
fluctuations49.
Co-administration strategies of IR and CR have also been tried in PwPD in order
to increase effectiveness of levodopa therapy. This strategy has shown to increase total
exposure of IR by 30-40% and prolongs levodopa half-life to 2.4 hours10. This
combination inhibits peripheral levodopa metabolism and allows more levodopa to enter
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the CNS10. This strategy has been shown to produce levodopa plasma profiles similar to
CR but with higher levodopa fluctuations61. However, the scheduling of this formula may
increase the burden or complexity of the medication schedule as the first dosage needs to
be taken early in the morning and restricts the CR at night10.
Levodopa is the most effective medication to control PD motor sequelae in,
independent of patient age and severity that will be prescribed depending on onset of PD
and degree of sequelae. However, there is other issues associated with consumption.
People with Parkinson’s should talk with their healthcare providers on which treatment
would be most beneficial for them and their lifestyle. It is also important to take
nutritional status into consideration when discussing levodopa therapies as long-term use
of this medication can negatively impact nutritional status which has been shown to
already deteriorate with PD progression. Specifically, one major nutritional concern is the
contraindication with protein, which will be discussed in greater detail later.
b. Non-motor Sequelae Management
Close to 100% of PwPD present with one or more of the non-motor sequelae.
Non-motor sequelae can be broad, like depression or cognitive impairment, or narrow,
like hallucinations, orthostatic hypotension, or sialorrhea (increase in saliva) 41, 62-64. Nonmotor sequelae may present as part of disease, or as a side effect of a PD medication used
to treat the motor sequelae (described above) and both, the sequelae and the medication
will fluctuate as the disease progresses41. It is important to consider the pharmacological
management of these sequaela as they may affect overall nutritional status, dietary intake
and quality of life in PwPD.
A common broad non-motor sequelae is depression that often occurs throughout
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the disease course and may worsen as the disease progresses 41. In 2013 a systematic
review65, and two meta-analyses66, 67, reviewed antidepressants effect on depression and
found no statistically significant superior antidepressant compared with a placebo, but
tricyclic antidepressants were more effective than selective serotonin receptor inhibitors
(SSRIs) and dopamine agonists (mirapex). The AMA suggests that SSRIs and selective
serotonin norepinephrine reuptake inhibitors (SNRIs) can be effective in managing
depression despite the little evidence found in PwPD41. Despite the positive effects,
tricyclic antidepressants are not frequently recommended due to the adverse effects that
may occur in older adults who are cognitively impaired41. Dopamine agonists are also an
option to target depression as it can improve motor symptoms as well41. The use of
antidepressants in PwPD is very common to treat depression and 13-22% of those who
are community-dwelling, and 50% of those who are institutionalized use
antidepressants68, which also an effect on cognition and quality of life (QoL), and can
lead to a decreased nutritional status. Therefore, it is crucial to identify eating patterns in
PwPD.
There have been few studies that have assessed the treatment of cognitive
impairment in PwPD. The most studied class of drugs have been cholinesterase
inhibitors in five placebo-controlled trials69, 70, that have shown improvements in global
assessment scale scores, cognitive function, behavioral disturbance and ADLs ins patients
with Parkinson’s disease dementia. However, with these drugs, the AMA believes that
meaningful clinical benefit of these drugs is variable and unpredictable in PwPD, and
research into other drugs to help with this non-motor sequelae needs to be conducted41.
Cognitive impairment has shown to decrease nutritional status, performance in activities
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of daily living31, 71, 72, quality of life, and increase caregiver burden26
The narrow non-motor sequelae, hallucinations, orthostatic hypotension, and
sialorrhea may also occur as a part of normal disease sequelae or may be a side-effect of
a PD medication41. Hallucinations, perceptions of things that are not present, have been
treated with clozapine, but there is a risk of leukopenia, which will require frequent blood
monitoring41. Also, for those with dementia, rivastigmine has shown to reduce
hallucinations73, while donepezil has shown to reduce hallucinations in those without
dementia74. Domperidone, has been recommended by the AMA to control dopamine
agonist- and levodopa- induced, hypotension especially when the medications are
introduced together41. The use of anticholinergic drugs for the treatment of sialorrhea has
been recommended by the AMA, however, these are not well tolerated in older adults
with cognitive dysfunction41. Glycopyrrolate may be very effective and better tolerated
due to limited blood-brain barrier penetration, and botox injections can be effective and
well tolerated, but with more injections, the risk of adverse effects like dysphagia may
limit use41.
Pharmacological management strategies for motor and non-motor sequelae are
often the first line of treatment for PwPD41. It is important to consider all medications
that the PwPD is taking, and be aware of the adverse effects that may impact nutritional
status, dietary intake and quality of life. Other approaches to compliment
pharmacological management of non-motor sequela may include dietary or occupational
health measures like, increasing salt and fluid consumption, elevating the head of the bed,
and quickly drinking 2, 8-oz glasses of cold water in the case of orthostatic
hypotension41. For more broad motor or non-motor sequelae, surgeries and ancillary
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services are recommended to be used in conjunction with pharmacological management
for better health outcomes75
IV.

Non-Pharmacological Management
Parkinson’s disease is a progressive disease that causes decline in motor,

cognitive and nutritional functioning. Pharmacological management is often started at
disease onset and will be monitored and altered throughout its progression. In addition to
pharmaceuticals, there are potential non-pharmacological management strategies like,
surgeries and ancillary services recommended for symptom management and to slow
disease progression76. The most common surgery for PwPD is Deep Brain Stimulation
(DBS), while the most common services for PD include physical and exercise therapies,
occupational therapy, speech therapy, and a growing need for nutritional therapy77. There
is currently no cure for Parkinson’s disease so, the recommended medications, surgeries
and services will all work in combination to manage the disease progression76.
a. Deep Brain Stimulation
Deep brain stimulation (DBS) has recently emerged as an effective treatment for
PwPD who no longer receive symptomatic relief from medications 76. Worldwide, there
are over 100,000 PwPD who have undergone DBS, and more are expected to receive the
treatment76, 78. An electrode implanted in the brain sends an electrical current to a neurostimulator in the chest, which blocks dysfunctional signals that cause motor
fluctuations79. Research conducted on the benefits of DBS have shown profound
improvements related to motor and speech sequelae79-81. A recent meta-analysis of 6randomized controlled trials found that DBS improved motor functioning while off
medication79. Schupbch et al80 found significant and sustained motor sequelae five years
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after surgery. Another study compared speech one year before and after in one group who
was treated with DBS, and another who was only treated with medication81. Only those
who received DBS experiences a significant decrease in speech intelligibility, strained
voice and stuttering, only from those who received DBS81. While DBS may impact
speech, it is an effective treatment option for managing overall disease sequelae 76.
However, because this is not the first line of treatment, and is only utilized in a small
population of PwPD, the use of ancillary services is recommended with the use of
pharmacological management, whether DBS was preformed or no to reduce side effects
and optimize symptoms outcomes76.
b. Ancillary Services
The American Academy of Neurology recommends regular utilization of
physical, occupational and speech therapies for PwPD82. These therapies have been
shown to improve quality of life, dysarthria and hypophonia in PwPD38, 83-85. The positive
effects of rehabilitation services slowing disease progression in PD have been well
documented. However, a recent study showed that only 25% of US Medicare
beneficiaries with PD received rehabilitative therapies in a 3-year period86, potentially
due to poor dissemination and implementation of PD research. Therefore, it is important
for PwPD to have a multidisciplinary team where primary care doctors and neurologists
recommend these rehabilitation services for better management of PD progression.
Regular attendance at these rehabilitation services, or one-on-one sessions has shown
improvements in motor function, activities of daily living, speech volume, cognition and
quality of life86.
Physical and Exercise Therapies
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Physical activity in the management of PD was first introduced in 1950 87. It was
not until three decades later that experimental studies were used to recognize the benefits
that physical and exercise therapies had on motor fluctuations in people with Parkinson’s
disease (PwPD) 88, 89. Physical and exercise therapies are the most utilized rehabilitation
service for PD and randomized controlled trials show its significant impact on improving
motor and non-motor sequelae, activities of daily living (ADL), speech volume and
QoL90. Common physical and exercise therapies include resistance training, tai chi, water
exercises, robotic gait training, dance, virtual reality, aerobic training, boxing, Nordic and
downhill walking91, 92. As most of these exercises serve to improve physical mobility and
functioning, activities such as dancing, water exercises, virtual reality training, and
Nordic walking have also allowed PwPD to enjoy greater health and wellbeing 91, 92.
Many studies have demonstrated that older adults enjoy different activities that
are not typical exercises because they add enjoyment. Tai chi has shown to provide the
most improvement in postural stability, movement function and gait in people with mild
to moderate PD93-95. These improvements can be maintained into the long-term (3
months) and still prove to be beneficial as the disease progresses 93-95. Also, dancing is a
complex motor skill that involves postural stability, weigh shifting, inter-limb
coordination, single leg-stance activities and trunk rotation96. Older adults have been
identified as a population to enjoy dancing as a form of physical activity97-99. In PwPD,
this exercise has shown benefits in body function, disease severity and QoL 99.
More traditional exercises like resistance and aerobic training, walking, boxing
and water exercises. Resistance training which may include exercise machines, has
resulted in improved lower limb muscle strength, balance and motor symptoms 100.
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Aerobic training through use of a cycle ergometer was used as aerobic training,
improvements in functional mobility, ADL, balance, disease severity and walking101.
Different types of walking training, Nordic and downhill have both been tested and show
benefits in functional mobility, gait, QoL and improvements in walking, respectively102,
103.

Boxing is becoming a common activity for PwPD because there have been

improvements in functional mobility, ADL, gait and balance in PwPD 104. Water exercises
have been thoroughly tested in older adult literature as the effects of buoyancy and
hydrostatic pressure of water has contributed to a decreased risk of falls105. For PwPD,
the aquatic environment may enhance balance, reduce freezing or gait and fear of falling
and increase movement of amplitude and speed96, 106, 107.
In addition to traditional physical activities, there have been many technological
creations to exercise to complement physical activities. Robotic gait training involves a
large device where one’s legs are strapped into a machine and moved on a treadmill108,
109

. This type of complementary exercise has improvements in functional mobility,

balance, disease severity, gait108, 109. Virtual reality and exercise gaming have also been
proposed to complement and practice to exercise therapy in those with neurological
disorders110, 111. With this technology, there improvements have been shown in functional
mobility, ADL, gait, QoL, balance and movement disorders 110, 111. A final technology, the
whole-body vibration, transits energy into your body, forcing your muscles to contract
and relax each second, which can provide modest improvements in the short term for
mobility, gait, balance and disease severity112. Although these new therapies can improve
motor functioning, when compared to physical therapies the improvements are not as
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positive and it is suggested that these technologies are used in conjunction with additional
physical activities91.
Occupational Therapy
Occupational therapists are trained to help PwPD maintain their usual level of
self-care, work and leisure activity for as long as possible113. Possible interventions may
include re-organizing the daily routine, learning new skills for alternative or adaptive
ways to carry out activities, providing or advising on specialized equipment or resources
and patient education (like devices to increase mealtime experience) 113. Multiple studies
have examined the use of an occupational therapist and results have shown that only 1325% of PwPD have utilized their services113-115. Most patients are not referred to an
occupational therapist until the later stages of the disease where the occupational therapist
helps to reduce daily stress, minimize disability and improve quality of life despite the
natural increase in impairment113.
Speech Therapy
Over 89% of PwPD will have a speech disorder and/or dysphagia throughout the
progression of their disease which will require pharmacological and nonpharmacological
management strategies86. Communication and speech deficits are often apart of the
disease sequelae, and are difficult to manage with medications or DBS alone 4, which will
require the specialty of a Speech Language Pathologist (SLP) to provide ancillary
services. The most common treatments for communication deficits include, the Lee
Silverman Voice Treatment (LSVT), or effort-based therapy, speech and voice therapy
and musical therapy4. The best outcomes have been shown with LSVT, which focuses on
increasing vocal loudness, voice quality, speech ineligibility, articulation116-118, and more
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evidence has been found surrounding positive changes in facial expression119 and
swallowing120. This treatment is time-intensive as it includes 16, 1-hour long sessions,
delivered over 4 weeks119, but has been tested in an 8-week time period with the same
positive results121.
Treatments for dysphagia are patient-dependent and will depend upon the
physiology of the swallowing for the safest approach4. Often, modification of textures
and consistencies of foods and liquids with thickeners will depend on barium swallow
testing. Honey-thickened liquids have been shown to result in the fewest aspiration
events, but for patient QoL purposes, the chin-down feeding approach was better
accepted122. Exercise programs like, expiratory muscle strength training (EMST) have
also been used to improve cough, swallow function, penetration/aspiration scores, and
hyolaryngeal function123, 124.
Parkinson’s disease sequelae will progress overtime and warrant the need for
ancillary services. While it would be beneficial for ancillary services to be started early,
most will not start until later. The motor (tremors and rigidity) and non-motor (dysphagia
and altered gastric emptying) sequelae can be managed with DBS, physical, speech and
occupation therapies and pharmacological therapies. However, these sequelae may
contribute to a larger issue of under/over-nutrition which will call for nutritional services
to be a part of the interdisciplinary team.
V.

Dietary Management
Optimal nutritional status is difficult for PwPD to maintain as cognitive decline,

weight fluctuations, difficulty swallowing and gastrointestinal issues contribute to
inadequate dietary intakes1, 5-7. Poor dietary intake result in poor nutritional status and
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risk39. Currently, there have not been any nutrition assessment tools that have been
validated in PwPD. However, the Dietary Screening Tool (DST) and Mini Nutrition
Assessment (MNA) are reliable and validated tools to identify severity of nutritional
status and risk in older adults, and have been used to identify PwPD with impaired
nutritional status and at nutritional risk32, 39, 125. There have been dietary
recommendations suggested that address PD sequelae and medication interaction17,
however no person with PD is alike and all will require a nutritional assessment for
individualized dietary recommendations. Therefore, the review will address several
nutritional issues that relate to PD that should be taken into consideration when caring for
a patient with PD.
Cognitive Decline
Dementia, the most common cognitive symptom, occurs in 40% of PwPD and is
associated with an accelerated progression of disease and risk for institutionalization29, 126,
127

. Cognitive decline has shown to affect interest in food through loss of taste and smell

senses, and eating habits in PwPD128, 129. The memory loss associated with cognitive
decline affects ones’ ability to remember to eat, placing the feeding on the caregiver, if
applicable130. Also, over the last few years there has been evidence of the gut-brain axis
that links the gut to the source of PD pathology that eventually progresses to
neurodegeneration131. The inclusion of phytochemicals and antioxidants from berries,
wine, caffeine have been suggested to have neuroprotective effects and may slow
progression of PD132.
Weight Changes
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Weight status in PD will vary based on disease stage and severity. Studies have
shown that the prevalence of obesity among PwPD is 50% higher than the general
population133. Obesity is associated with impaired glucose control, hypertension,
dyslipidemia, and cardiovascular disease, all of which will further effect PwPD, aside
from typical disease sequelae133. If the PwPD is not obese at diagnosis, they may become
obese preceding initial diagnosis due to an increase in energy intake, or the initiation of
DBS or a dopamine agonist medication, all of which will increase energy intake 134, 135.
Although weight and energy intake may increase during these times, a major sequela of
PD is weight loss and eventual undernutrition, 5, 136 partly due to rigidity and dyskinesia
(~400kcals/day) 137-140. Weight loss is associated with increased energy expenditure, early
satiety due to decreased gastrointestinal motility, olfactory impairment, bulbar
dysfunction and decreased baseline dopaminergic stimulation of central reward
systems135.
Additionally motor sequela have an negative effect on activities of daily living
related to food intake like, shopping, preparing, and cooking which may also reduce food
intake141. A 3-year longitudinal study showed that increasing energy intake to
compensate for the increased expenditure was not effective in preventing weight loss,
suggesting that the idea of progression weight loss in PD may be related to other factors
like malabsorption125. Weight fluctuation is a major concern in PD due to muscle wasting
which can impact cognitive functioning and ability to carry out activities of daily living,
which will increase caregiver burden5.
Dysphagia
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Difficulty swallowing (dysphagia) is a common sequela that presents in up to
80% of PwPD142-144. Tremors and rigidity occurs in the head and neck regions with PD,
therefore chewing and swallowing can be effected145, 146. There are functional changes in
the oropharyngeal and esophageal motility of the neck which impair peristalsis and low
sphincter activity to further disrupt gastric functioning147, 148. Assessment of dysphagia
includes clinical parameters like, changes in BMI, HY-scale, food and drink retention,
and questionnaires addressing self-reported perception of swallowing149. Dysphagia is
believed to play a role in weight loss in PD, because it results in prolonged feeding
periods, mealtime interruptions, and avoidance of certain foods, specifically solid foods
145, 146 150, 151.

Liquid foods are usually associated with dehydration and risk for aspiration

due to dry oral organs (dry mouth) 150, 151. Both textures can all lead to nutrient
deficiencies. Texture-modified diets and the use of thickened whole-formulations and
ready-to-eat foods are often recommended for use as they can be safer to swallow in
PwPD5. Dietitians and SLPs should work together to identify the best texture for the
individual and if it is meeting their nutrient needs. If nutrient needs are not able to be met,
a gastrostomy may be indicated5.
Gastrointestinal Issues
Impaired gastric emptying rate is a severe motor sequelae that increasingly occurs
with PD progression152. Changes in gastric motility (ex. reduced absorption related to
dopaminergic activity) play a large role on small intestine transit, through enhanced
production of bacteria and malabsorption due to alterations of the enterocytes153, 154.
Impaired gastric emptying in PwPD is that it may prolong the exposure of levodopa to
the decarboxylase enzyme in the gastric mucosa, delaying absorption in the guts and its
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overall efficiency in reducing motor fluctuations 153, 154. Decreased gastric emptying rate
will increase abdominal distention, discomfort, nausea and early satiety and bloating,
which may reduce the enjoyment of eating and energy intake in PwPD 5.

Constipation

is the most commonly reported gastrointestinal sequela for PwPD, and impacts nearly
60% of PwPD throughout the course of their disease5. Increased transit time and gut
dysbiosis are factors that contribute to constipation, and are contraindicated in PwPD as
this will highly degrade their levodopa medication and reduce its availability5. Dietary
strategies to address constipation include increase in fiber and water intakes. People with
PD have been shown to consume adequate fiber to alleviate their constipation however,
this population has also been shown to consume less water, which negatively effects stool
consistency and bowel habits11. Therefore, when education PwPD on how to alleviate
constipation, increases in water and fiber must be discussed in unison11.
a. General Recommendations for Dietary Intake
Nutrition assessment is critical for PwPD as the associated motor and non-motor
sequelae can negatively impact dietary intake and nutritional status and vice versa.
However, there is a lack of specific dietary recommendations for PwPD to manage
sequelae. People with PD will need to monitor nutrients like protein, water, fiber,
calcium, vitamin D and B6 and folate. It has been recommended that PwPD should
consume at least 1.5L of water per day and consume a minimum of 30-35g of fiber per
day5. The dietary guidelines for Americans (DGAs) may be used to form a base for
recommendations in this population as they promote a balanced and nutritious diet that
includes fruits, vegetables, protein, grains and dairy40. The recommendations for this diet
include 10-35% of calories from protein sources, 45-65% of calories from carbohydrates
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and 20-35% of calories from fats with <10% of calories from added sugars and saturated
fats, but all breakdowns and items from food groups should be individualized to fit the
needs of the person with PD40. The Mediterranean diet has been studied within this
population and is associated with reduced PD incidence and later age of diagnosis 5. It is
typically 50-60% carbohydrates, 12-15% protein and 25-30% fat, which is a small change
from the DGAs5. The Mediterranean diet focuses on fruits, vegetables, nuts, seeds, fish
and other lean protein, including fish high in DHA and EPA like salmon, tuna and
swordfish that have been shown to improve neuronal health and slow PD progression 132.
The DGAs or Mediterranean diet may be utilized early in the diagnosis but once
levodopa therapy is introduced, protein intake may need to be altered so the medication
absorption can be improved5.
b. Dietary Protein Patterns
Dietary protein is essential as it promotes muscle mass retention, growth, and
physical functioning1, 2, 11. However, all dietary protein can interfere with absorption of
levodopa-containing medication in the gut, blood brain barrier, and the peripheral
nervous system19, 155. Specifically, the large neutral amino acids, phenylalanine, tyrosine,
and tryptophan, which are commonly found in protein foods like dairy products, nuts,
seeds, salmon and turkey, will have the most competition. Therefore, it is recommended
that levodopa be consumed anywhere from 30-120 minutes before or after a proteincontaining meal or snack11. Persons with PD consume up to 50% more protein than the
Recommended Dietary Allowance (RDA), 1.2g/kg vs. 0.8g/kg respectively, and a higher
protein intake is associated with a higher daily levodopa dose over time, due to the
contraindication of protein and levodopa11.As stated above the higher doses of levodopa
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can be ineffective in reducing motor sequelae11, 12. Also, studies have shown that 22%
(n=364)156 and 38% (n=52)155 of their participants alter the timing of their dietary protein
intake to reduce motor fluctuations. There have been PD-specific dietary
recommendations, the LPD and PRD, that aim to reduce PLI experienced by PwPD but
both may not maintain a healthy diet11, 15, 16, 18, 19.
The American Academy of Neurology recommends a LPD or PRD to minimize
PLI and reduce motor fluctuations in PwPD 15, 16. A LPD restricts total daily protein
intake to 0.5g/kg/day15. Low protein diets in conjunction with levodopa have been tested
in randomized clinical trials in an attempt to reduce motor sequelae in PwPD. Two
studies have reported on the effectiveness of motor fluctuations with levodopa on five
protein altered diets ranging from 10g/day (0.15g/kg/day in 70kg person) to 2g/kg/day18,
19.

The most control on motor symptoms occurred in the diets providing 0.5g/kg, also, as

protein intake increased to 2g/kg, there was a decrease in symptom control. Participants
in these studies continued to follow the 0.5g/kg protein diet 2-12 months after the study
ended and were able to reduce their levodopa dosage from 20-42%18, 19. The results from
these studies suggest that restricting protein is effective in controlling PD sequelae and
may reduce the dependence on levodopa therapy. However, although participant
acceptance was shown, other studies have not and this may not be the best option due to
outcomes changes like lean body mass, muscle strength and ADL’s which were not
measured in the present studies, but all may be impacted by low protein intake, especially
in the aging population1, 2, 11.
The PRD may be a better option for aging adults with PD as it focuses on
reducing dietary protein prior to the evening meal, and consuming an unlimited amount
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of protein at the evening meal11, 15, 17-19. This diet does not limit total protein and most
studies have tested between 7-15g of protein before the evening meal with a goal of
0.8g/kg of protein daily (70kg body weight= 41-48g at dinner) 157-160. In a case-controlled
study that investigated 600 PwPD, overall daily protein intake influenced levodoparelated motor complications11. A daily dietary protein intake 10 grams over the
individual’s recommendation of 0.8/g/kg (70kg body weight= 66g) was predictive for an
increase in levodopa dose by 0.7mg/kg/day (70kg body weight =~50mg additional
levodopa/day). A multivariate regression analysis determined an inverse association
between PRD and motor fluctuations (p=0.046)11. From this study, it can be speculated
that levodopa dosage may increase at a slower rate, may be effective for a longer time
and therefore help with motor fluctuations for a longer time, if the PRD with protein
intake at 0.8g/kg/day is practiced.
There are multiple studies that support the use of Mediterranean and modified
protein diets for PwPD5, 11, 15, 17, 19. Also, the use of low-protein supplements may be used
to meet dietary recommendations157. Other dietary patterns such as, the consumption of
dairy products (milk, cheese, ice cream and yogurt), canned fruits and vegetables, diet
sodas (due to the aspartame), fried foods, beef have shown to negatively affect PD
progression, but have not been as extensively studied and have shown inconclusive
results132. The conflicting dietary evidence may add to the confusion that PwPD and their
caregivers already experience with the disease20, 29.
VI.

Caregivers
Parkinson’s disease is the second most prevalent neurodegenerative disease that

affects the ability to perform ADLs, participate in social activities and access medical
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care42. Additionally, dementia, the most common cognitive symptom, occurs in 40% of
PwPD and is associated with an accelerated progression of disease and risk for
institutionalization29, 126, 127. Therefore, PwPD often require formal (paid) and informal
(unpaid) caregivers are necessary to provide physical, psychosocial and cognitive support
for PwPD42. The scope of this review will focus on informal caregivers which spend up
to 39 hours of care per week and, the costs of caregiving have shown to incur the second
largest economic burden on a family9.
It is estimated that 80% of caregivers for PwPD are informal and, are typically a
spouse/partner or other immediate family member161. Informal caregiving for those with
neurological disorders has been extensively studied and has showed improved health
outcomes, treatment adherence, quality of care and decreased risk of institutionalization
for the PwPD162-165. However, the time and efforts put into caregiving have negative
effects on the caregivers’ quality of life, especially if a woman is caring for a male with
PD42. The burden associated with caregiving for this population is often due to the many
medications, therapies, doctor’s appointments and overall decline in functional ability that
are associated with PD which the caregiver must take on25. Through the use of
qualitative, quantitative, and mixed-methods studies, caregivers often report an
information deficit regarding dietary and medication management for PwPD, all
contributing to the feelings of stress regarding care of PwPD 20, 23-30.
Caregivers are highly involved in medication management in PD 23. A qualitative
study by Shin et al20 investigated the challenges and strategies to medication adherence in
16 PwPD and 5 caregivers. In this patient-caregiver dyad study, the participants’ main
concerns were increased cost of medication, medication compliance and decreased
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levodopa response overtime. Specifically, the dyads reported feeling stress and
uncertainty about the timing of levodopa and meals 20. The reported information deficit
regarding PLI in this study affirms the need to identify the specific knowledge and
attitudes regarding dietary protein, levodopa management and overall dietary habits in
PwPD as is has not been the aim of qualitative research thus far. It is important to include
caregivers in dyadic studies when assessing PwPD because caregivers often shoulder the
burden of PD progression as the cognitive status of the PwPD may be compromised due
to disease sequelae24, 25, 29, 39, 126, 127.

VII.

Conclusion
There is often confusion within the PwPD-caregiver dyad for effective dietary

protein modification when taking levodopa-containing medications15, 17, 20. Persons with
PD should limit protein when consumed concurrently with levodopa during the day to
attenuate motor fluctuations19, 155, 166, 167. However, consistent recommendations are not
available; various protein levels, and timed delays between medication and meal
consumption exist11, 20. Informal caregivers help manage daily tasks for PwPD including
medication and meal management because PD sequelae typically decreases the ability to
function independently23, 25. As PwPD have been identified as a population at possible
nutrition risk, caregivers should be cognizant of foods that promote optimal health and
attenuate PLI. The purpose of this cross-sectional, mixed methods study is to obtain
qualitative information related to dietary knowledge, attitudes, and behaviors in regards
to PLI as reported by PwPD and their caregivers, and to assess nutritional risk and daily
dietary intake within PwPD. This data provide insight to what PwPD and their caregivers
believe about diet and levodopa management for healthcare professionals.
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Appendix B: Extended Methodology

Methods:
This cross-sectional, mixed-methods study was conducted from October 2017 to
January 2018 when approval was granted from the University of Rhode Island (URI)
Institutional Review Board (IRB). People with Parkinson’s disease and their ICG were
from, posting of flyers and personal visits to, PD health clinics and rehabilitation centers,
and hospitals and universities throughout Rhode Island. In order to participate, all
participants needed to be community-dwelling adults aged 18 and older and have access
to a telephone. The PwPD needed to self-reported their disease stage based on the HY
scale (stage 1-4)31 and adherence to taking at least 1 levodopa-containing medication. All
ICG needed to be informal, meaning they were an unpaid family member/friend who
provides the majority of care to the PwPD21-23. Participants were excluded if they
received calories from enteral/parenteral nutrition, reported a HY stage 5, or scored ≤18
on the T-MoCA. The sample size for this mixed-methods study included 10 dyads, with
10 interviews total which has shown to be an appropriate number for data saturation in
this population20, 28, 168-170 .
This study was completed in 3 assessments, two-telephone calls and one home
visit. The first assessment was a screening phone call with the primary author where the
PwPD completed the T-MoCA and all participants reviewed inclusion criteria. The
informed consent process was then conducted over the telephone. Assessment #2 was
another telephone consisted of the DST and the first 24HR. All participants completing
the 24HR recall were mailed a food amount booklet for estimating portion sizes.
Assessment #3 was a home visit with the primary author, where the past medical history
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(PMH), a second 24HR and a 21-question semi-structured interview were completed.
Dyadic interviewing (inclusion of two people in one interview) was used during the
second and third assessments, as this method has shown to provide insight to strengths
and strategies for coping with sequelae171
Qualitative Methods
Ten dyads were interviewed for this study (10 PwPD and their 10 caregivers).
This sample size is consistent with past qualitative research to provide sufficient
theoretical saturation (the point at which there is no significant new data) and yield
sufficiently dense data with diverse experiences and perspectives 20, 28, 168-170. Semistructured interview questions were created by the research team to explore Eating
Environment, Dietary Intake, and Medication Management. The questions were piloted
to 3 dyads prior to the start of this study in order to determine content validity and
understandability of the survey. Based on these pilots, questions were formatted to be
more directed to the PwPD, for example “How has your diet changed since you have
been diagnosed with PD” these changes allowed more insight from the PwPD. Also, in
order to identify where the knowledge gap is within the dyad, questions were formatted
to be more open-ended, “Is there anything you would like to know about the foods you
eat or your daily nutrition in general?” This question gave us great insight to the PLI the
PwPD experienced as most addressed this concern during the interview. In the original
interview, there was not a question about how long the PwPD have been on levodopa or
how many times per day they take the medication, so this was added.
The interviews were conducted face-to-face at the participant’s home with the
PwPD and their informal caregiver and primary author present. All interviews were
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audio-recorded, transcribed verbatim and coded using thematic qualitative content
analysis34. The primary author and research assistant reviewed and coded the transcripts
separately, then discussed their findings to identify the most common themes from each
interview, and generated the final themes together. The two researchers then used nVivo
11 QSR (International Pty Ltd, Victoria Australia) to code for final key themes as it is
shown to be useful for enhancing the analytical capacity of qualitative data172. The final
key themes for coding were: 1. Barriers to Dietary Intake, 2. Lack of Nutrition
Knowledge for PD, 3. Reliance on ICG Buying and Preparing Foods, 4. Reduced
Enjoyment of Foods and Meal Times, 5. Barriers to Medication Management, 6.
Management of Symptoms, and 7. Access to Medication Information. Qualitative content
was summarized and direct quotes were used to illustrate the perspectives of the
participants. Participants with PD are identified in the text as “PD” followed by a number
that was assigned sequentially as surveys were completed. The participants who were
caregivers are identified in the text as “CG” followed by a number that was assigned
sequentially as surveys were completed.
Quantitative Methods
Nutritional risk status through use of the DST32 and nutritional intake through use
of the Nutrition Data System for Research (NDSR). The DST is a 25-item questionnaire
that identifies dietary patterns and nutritional risk. The sub components are: whole fruit
and juice, vegetables, lean proteins, added fats, sugars and sweets, dairy and processed
meats, and use of dietary supplements. A total score ranging from 0-105 was calculated
and categorized with one of three different nutritional risk levels; (<60) at risk, (60-75)
possible risk, and (>75) not at risk32.
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Two 24HR were collected using NDSR. Dietary intake data was gathered by the
multiple-pass interview approach33, which included a respondent-driven 5-step process:
1) Quick List to collect a list of foods and beverages consumed the previous day, 2)
Forgotten Foods to probe for forgotten foods, 3) Time and Occasion to collect the time
and eating occasion for each food, 4) Detail Cycle to collect a detailed description of each
food including amount and additions, and review the 24HR day, 5) Final Probe to probe
for anything else that has been consumed173.
Additional Measures
Anthropometrics. Height was measured in cm by use of stadiometer (Detetco,
Webb City Missouri), and weight will be measured in kg using a scale (Tanita BF-556,
Arlington Heights, Illinois). Body mass index (BMI) was calculated by kg of body
weight/height in meters2, and classified according to predetermined categories:
underweight= <18.5kg/m2, normal weight= 18.5-24.9kg/m2, overweight= 25-29.9kg/m2
and obese ≥30kg/m2 174.
Disease Staging. Self-reported HY scores were assessed as the disease stage from
1, “unilateral disease”, 1.5 “unilateral plus axial involvement”, 2 “bilateral disease
without impairment of balance”, 2.5 “mild bilateral disease with recovery on pull test”,
or, 3 “mild to moderate bilateral disease, some postural instability, physically
independent”31.
Past Medical History. PwPD completed a medical history questionnaire to
identify current and prior health-related conditions of PwPD. The topics addressed in this
questionnaire included neurological, endocrine and cardiovascular health.
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Cognitive Functioning. The T-MoCA is a valid telephone test of cognition
includes 8 subtests that consist of digit span, attention, calculation, repetition, verbal
fluency, abstraction, recall and orientation175. Total possible score on this assessment is
22.
Statistical Analysis
Data from the questionnaires and home visits was analyzed using SPSS Version
25 (IBM Corp, New York). Normality was assessed using skewness and kurtosis.
Pearson’s correlations were used for the normally distributed data, and Spearman’s
correlations were used for the data that was not normally distributed. Categorical
variables are reported as numbers and percentages. Frequencies were used to determine
which participants are at nutritional risk, possibly at risk and not at risk based on DST
scores. Continuous variables are reported as mean ± standard deviation. The DST will be
a continuous variable to identify the number and percent of participants found at nutrition
risk, possible risk and not at nutrition risk. Data from the 24HR recalls is reported as
mean macronutrient intake and g/kg protein consumed. Level of significance was set at a
p-value of <0.05.
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Appendix C: Consent forms for Research

Knowledge, attitudes and behaviors for the dietary
management of Parkinson’s disease Oral Consent Script for
Research Consent for Caregiver
“Before we begin, I want to review a few things with you.
• Can you fluently speak English?
• Are you 18 years or older?
• Do you live at home?
• Are you an unpaid caretaker of a person with Parkinson’s disease?
• Do you have access to a telephone?
• We will be completing a short questionnaire that will require you to recall
words, identify letters and numbers, subtract, repeat phrases and make
similarities (T-MoCA)”.
BACKGROUND
The purpose of this research study is to describe dietary knowledge, attitudes, and behaviors
in regards to the protein-levodopa interaction as reported by people with Parkinson’s
disease and their caregivers. Additionally, to better understand dietary quality and intake of
people with Parkinson’s disease, nutrition risk status and dietary intake will be examined.
This data will provide insight to healthcare professionals about what people with Parkinson’s
disease and their caregivers understand and do about diet and levodopa management.
You are being invited to take part in a research study. Before you decide to participate, it is
important for you to understand why the research is being done and what it will involve. Ask
us if there is anything that is not clear or if you would like more information. Take time to
decide whether you want to volunteer to take part in this study.
STUDY PROCEDURE
This study will be completed at three Time Points that will all occur one month of each other.
The first two Time Points will take place via telephone call, and the final will be a home visit.
The total study time is expected to take three and one-half hours depending on how much you
want to speak about each item on the questionnaires. The three time points are described
below. Your participation in this interview is completely voluntary; you may choose not to
participate. If there are any questions you do not wish to answer, just let me know and we can
skip it. You can stop the interview at any time. Our conversation will be kept completely
confidential and your responses will remain confidential. I am in a private office and will be
using a speakerphone. No one else will be in the room with me. If you agree, our conversation
will be tape-recorded in order to document your exact words. The tapes will be destroyed at
the end of this project. The transcripts will be numbered and will not contain your name or
any identifying information.
Time Point #1 (~35 minutes) _
• This will be completed on the phone.
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•
•

Review of inclusion and exclusion criteria.
Complete the informed consent process.

Time Point #2 (~55 minutes)
• This will be completed on the phone.
• The inclusion of you and your caregiver in one interview (dyadic interviewing) will be
used from this time point on, but, all dietary assessments (24- hour dietary recall and
dietary screening tool) will be completed for people with Parkinson’s only as the
scope of this study is the knowledge, attitudes and behaviors of people with
Parkinson’s in regards to dietary recommendations, especially concerning protein
due to the prominent food-drug interaction people with Parkinson’s may experience.
• Complete the Dietary Screening Tool. The Dietary Screening Tool is a 25-item
questionnaire that asks participants to report how frequently they consume various
types of food and will detect dietary patterns.
• Complete the first 24-hour. A 24-hour recall is a way to characterize nutritional intake
and consists of 5- steps to collect all of the foods and beverages that you have
consumed in the past 24 hours. The caretaker will be mailed a food amount booklet
for estimating portion sizes after the first Time Point.
Time Point #3 (~120 minutes)
• This will be completed in-person – a study staff member will complete it as a home visit.
• Complete the past medical history questionnaire. This questionnaire will
identify current and prior health-related conditions. The topics addressed in this
questionnaire will include neurological, endocrine and cardiovascular health.
• Complete the second 24-hr dietary recall.
• Complete the 21-question semi-structured interview. The study staff has designed
this interview. You and your caretaker will be asked to answer questions about your
eating environment, dietary intake, and medication management.
RISKS
The risks of this study are minimal.
BENEFITS
We cannot promise any direct benefit for taking part in this study. However, possible benefits
include customized dietary recommendations for your caretaker based on their 24-hour
recalls and the dietary screening tool answers. The recommendations will be generated by
study staff and reviewed by the Principal Investigator and the doctoral nutrition student, who
are registered dietitians, and sent to you approximately 1 month after Time Point #3.
CONFIDENTIALITY
We will keep all research records that identify you private to the extent allowed by law.
You will be assigned a participant number that will be kept with your responses from
the questionnaires, interview and dietary recalls. In publications, you will be identified
as “participant #”.
VOLUNTARY PARTICIPATION
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Research studies include only people who choose to take part. You can tell us that you
don’t want to be in this study. You can start the study and then choose to stop the study
later. This will not affect your relationship with the investigator or any groups you may be
involved in at the University of Rhode Island or related to Parkinson’s disease, and there
will be no penalty of loss of benefits to which the participant is otherwise entitled.
COSTS AND COMPENSATION TO PARTICIPANTS
You will not receive any compensation for your time in this study.
CONTACT INFORMATION
If you have any additional questions about this study please feel free to contact the principal
investigator, Dr. Ingrid Lofgren at 401-874-5706. You may also contact the Vice President for
Research and Economic Development at 401-874-4576.
CONSENT
I will be turning on the tape recorded now.
What questions do you have about the information that I have provided?
Do you consent to participating in this research study?

Knowledge, attitudes and behaviors for the dietary
management of Parkinson’s disease Oral Consent Script for
Research
Consent for Person with Parkinson’s disease
“Before we begin, I want to review a few things with you.
• Do you fluently speak English?
• Are you 18 years and older?
• Do you have Parkinson’s disease with a Hoehn-Yahr staging of 1-4?
• Do you live at home?
• Are you currently taking 1 levodopa containing medication?
• Do you have access to a telephone?
• We will be completing a short questionnaire that will require you to recall
words, identify letters and numbers, subtract, repeat phrases and make
similarities (T-MoCA)”.
BACKGROUND
The purpose of this research study is to describe dietary knowledge, attitudes, and behaviors
in regards to the protein-levodopa interaction as reported by people with Parkinson’s
disease and their caregivers. Additionally, to better understand dietary quality and intake of
people with Parkinson’s disease, nutrition risk status and dietary intake will be examined.
This data will provide insight to healthcare professionals about what people with Parkinson’s
disease and their caregivers understand and do about diet and levodopa management.
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You are being invited to take part in a research study. Before you decide to participate, it is
important for you to understand why the research is being done and what it will involve. Ask
us if there is anything that is not clear or if you would like more information. Take time to
decide whether you want to volunteer to take part in this study.
STUDY PROCEDURE
This study will be completed at three Time Points that will all occur one month of each other.
The first two Time Points will take place via telephone call, and the final will be a home visit.
The total study time is expected to take three and one-half hours, depending on how much
you want to speak about each item on the questionnaires. The three time points are described
below. Your participation in this interview is completely voluntary; you may choose not to
participate. If there are any questions you do not wish to answer, just let me know and we can
skip it. You can stop the interview at any time. Our conversation will be kept completely
confidential and your responses will remain confidential. I am in a private office and will be
using a speakerphone. No one else will be in the room with me. If you agree, our conversation
will be tape-recorded in order to document your exact words. The tapes will be destroyed at
the end of this project. The transcripts will be numbered and will not contain your name or
any identifying information.
Time Point #1 (~35 minutes) _
• This will be completed on the phone.
• Review of inclusion and exclusion criteria. This will include a short cognition test.
• Complete the informed consent process.
Time Point #2 (~55 minutes)
• This will be completed on the phone.
• Complete the Dietary Screening Tool. The Dietary Screening Tool is a 25-item
questionnaire that asks participants to report how frequently they consume
various types of food and will detect dietary patterns.
• Complete the first 24-hour dietary recall. A 24-hour recall is a way to characterize
nutritional intake and consists of 5- steps to collect all of the foods and beverages that
you have consumed in the past 24 hours. You will be mailed a food amount booklet
for estimating portion sizes after the first Time Point.
• Your caregiver may participate with you at this time point but, all dietary
assessments (24- hour dietary recall and dietary screening tool) will be based on your
diet and typical food consumption as the scope of this study is the knowledge,
attitudes and behaviors of people with Parkinson’s in regards to dietary
recommendations, especially concerning protein due to the prominent food-drug
interaction people with Parkinson’s may experience.
Time Point #3 (~120 minutes)
• This will be completed in-person – a study staff member will complete it as a home
visit. This visit will include you and your caregiver.
• Complete the past medical history questionnaire. This questionnaire will
identify current and prior health-related conditions. The topics addressed in this
questionnaire will include neurological, endocrine and cardiovascular health.
• Complete the second 24-hr dietary recall.
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•

Complete the 21-question semi-structured interview. The study staff has designed
this interview. You and your caregiver will be asked to answer questions about your
eating environment, dietary intake, and medication management.

RISKS
The risks of this study are minimal.
BENEFITS
We cannot promise any direct benefit for taking part in this study. However, possible
benefits include customized dietary recommendations based on their 24-hour recalls and
the dietary screening tool. The recommendations will be generated by study staff and
reviewed by the Principal Investigator and the doctoral nutrition student, who are
registered dietitians, and sent to you approximately 1 month after Time Point #3.
CONFIDENTIALITY
We will keep all research records that identify you private to the extent allowed by law.
You will be assigned a participant number that will be kept with your responses from
the questionnaires, interview and dietary recalls. In publications, you will be identified
as “participant #”.
VOLUNTARY PARTICIPATION
Research studies include only people who choose to take part. You can tell us that you
don’t want to be in this study. You can start the study and then choose to stop the study
later. This will not affect your relationship with the investigator or any groups you may be
involved in at the University of Rhode Island or related to Parkinson’s disease, and there
will be no penalty of loss of benefits to which the participant is otherwise entitled.
COSTS AND COMPENSATION TO PARTICIPANTS
You will not receive any compensation for your time in this study.
CONTACT INFORMATION
If you have any additional questions about this study please feel free to contact the principal
investigator, Dr. Ingrid Lofgren at 401-874-5706. You may also contact the Vice President for
Research and Economic Development at 401-874-4576.
CONSENT
I will be turning on the tape recorded now.
What questions do you have about the information that I have provided?
Do you consent to participating in this research study?
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Appendix D: Assessment Materials

Participants will complete two 24-hour recalls (24HR). The first 24HR will be done over the
phone (assessment #2) b and the second 24HR will be done in-person during a home visit
(assessment #3). A 24HR is when a person is asked to list and describe all the foods they
ate the previous day. Since people consume different foods and beverages, different
questions are asked during each 24HR. Participants will be encouraged to have labels of
foods they eat available during the assessments so exact information can be entered. This
project will be utilizing the Nutrition Data System for Research from the University of
Minnesota to collect the dietary data. Information on the program is attached.
For the most part, all participants will be asked the following questions. Many of these
questions will be asked multiple times.
• At what time did you get up yesterday?
• What was the first thing you had to eat or drink after getting up yesterday?
• What else did you have to eat with that (insert food or beverage)?
• What was added to that beverage?
• What else did you have at that meal?
• Was the (insert food or beverage) eaten plain or did you put something on it?
• What did you eat after that meal?
• What did you have for snacks yesterday?
• What was the brand of (insert food or beverage)?
• How many cans/bottles or juice/soda/water did you have at that time?
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•
•
•
•
•

What was the last thing you ate and drank yesterday?
What did you snack on after you last meal?
Did you get up during the night and eat anything?
About what size was the (insert food or beverage)?
Was the (insert food or beverage) an original product or was it modified in anyway?
For example, was it low sodium, low fat, cholesterol free, etc.?
• When was the first time you took your levodopa or levodopa containing medication?
• When was the next time you took your levodopa or levodopa containing medication?
Did you have anything to eat at this time?
Depending on dietary intake, these additional questions may be asked. Many of these
questions could be asked multiple times.
• Did you add any cream, milk, milk substitute to the coffee or tea?
• Did you add any sugar or sugar substitute to the coffee or tea?
• How much of the (insert food or beverage) did you eat?
• Were you able to finish all of that (insert food or beverage)?
• Was this (insert food) prepared with fat? If so, what type of fat?
• When preparing (insert food) was salt added?
• Was there frosting on the (insert food)?
• If so, about how much frosting?
• What was the flavor/color of the frosting?
• Did you add any condiments to (insert food)?
• If so, what condiments and how much of each?
• Was there ice in the (insert beverage)?
• Was the cake a single, double, or triple layer cake?
• Were there any seeds on the bagel?

Dietary Screening Tool
DIRECTIONS: Please check one response to each question that best describes
how you eat.

How often do you usually eat fruit as a snack?
____
____
____
____

Never
Less than once a week
1 or 2 times a week
3 or more times a week

How often do you usually eat whole grain breads?
____ Never or less than once a week
____ 1 or 2 times a week
____ 3 or more times a week
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How often do you usually eat whole grain cereals?
____ Never or less than once a week
____ 1 or 2 times a week
____ 3 or more times a week
How often do you usually eat candy or chocolate?
____ Never
____ Less than once a week
____ 1 or 2 times a week
____ 3 or more times a week
How often do you eat crackers, pretzels, chips, or popcorn?
____ Never
____ Less than once a week
____ 1 or 2 times a week
____ 3 or more times a week
How often do you eat cakes or pies?
____ Never
____ Less than once a week
____ 1 or 2 times a week
____ 3 or more times a week
How often do you eat cookies?
____ Never
____ Less than once a week
____ 1 or 2 times a week
____ 3 or more times a week
How often do you eat ice cream?
____ Never
____ Less than once a week
____ 1 or 2 times a week
____ 3 or more times a week
How often do you eat cold cuts, hot dogs, lunchmeats or deli
meats?
____ Never or less than once a week
____ 1 or 2 times a week
____ 3 or more times a week
How often do you eat bacon or sausage?
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____ Never or less than once a week
____ 1 or 2 times a week
____ 3 or more times a week

How often do you eat carrots, sweet potatoes, broccoli, or
spinach?
____
____
____
____

Never
Less than once a week
1 or 2 times a week
3 or more times a week

How often do you eat fruit (not including juice)? Please include
fresh, canned or frozen fruit.
____
____
____
____

Never or Less than once a week
1 or 2 times a week
3 to 5 times a week
Every day or almost every day

How often do you eat hot or cold breakfast cereal?
____ Never
____ Less than once a week
____ 1 or 2 times a week
____ 3 to 5 times a week
____ Every day or almost every day

How often do you drink some kind of juice at breakfast?
____
____
____
____

Never or Less than once a week
1 or 2 times a week
3 to 5 times a week
Every day or almost every day

How often do you eat chicken or turkey?
____ Never or less than once a week
____ 1 or 2 times a week
____ More than 3 times a week
How often do you drink a glass of milk?
____
____
____
____
____

Never or Less than once a week
1 or 2 times a week
3 to 5 times a week
Every day or almost every day
More than once every day
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Do you usually add butter or margarine to foods like bread,
rolls, or biscuits?
____ Yes
____ No
Do you usually add fat (butter, margarine or oil) to potatoes and
other vegetables?
____ Yes
____ No
Do you use gravy (when available) at meals?
____ Yes
____ No
Do you usually add sugar or honey to sweeten your coffee or
tea?
____ Yes
____ No
Do you usually drink wine, beer or other alcoholic beverages?
____ Yes
____ No
How often do you eat fish or seafood that IS NOT fried?
____ Never
____ Less than once a week
____ Once a week
____ More than once a week
How many servings of milk, cheese, or yogurt do you usually
have each DAY?
____ None
____ One
____ Two or more
How many different vegetable servings do you usually have at
your main meal of the day?
____
____
____
____

None
One
Two
Three or more
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Which of the following best describes your nutritional
supplement use.
____ I don’t use supplements
____ I use supplements other than vitamins and mineral
____ I use a multivitamin/mineral preparation (e.g. Centrum)

INTERVIEW
Knowledge, attitudes and behaviors for the dietary management of
Parkinson’s disease
Ingrid Lofgren, PhD, Principal Investigator
Leslie Mahler, PhD, CCC-SLP, co-Investigator
Version 1: 7-3-13
Participant Name:_________________________
______________

Initials: ___ ___ ___ ID#:

Name of Interviewer:_____________________________
Date:_________________
Emergency contact name and address & phone:
_______________________________________
_______________________________________

DIRECTIONS: Read the following questions out loud to each prospective volunteer
and record the answers. Any answers that require clarification should be written in the
space below the question or on the back of the sheet. Indicate whether any follow-up is
necessary or if any referrals are appropriate.
What is your neurological diagnosis? __________________________
When were you diagnosed? _________________________________
What were your symptoms at that
time?____________________________________________
________________________________________________________________________
____
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What are your symptoms now?
___________________________________________________
________________________________________________________________________
_____
What is your communication
like?_________________________________________________
________________________________________________________________________
_____
What is your diet like?
___________________________________________________________
What is your physical activity like?
_________________________________________________
Does your speech sound clear to other people?
_________________________________________
If not, how does it sound?
___________________________________________________
Can you think of the words that you want to say?
______________________________________
If you do have trouble, how often does it happen?
__________________________________
Are you experiencing any symptoms of a swallowing disorder?
_____________________________
If yes, what is the problem with your swallowing?
__________________________________
________________________________________________________________________
_____
What would you say is your most significant problem with speech or swallowing today?
________________________________________________________________________
______
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Did you experience any changes in your speech or swallowing before your diagnosis?
________
________________________________________________________________________
_____
Does medication affect your speech or voice or swallowing? _________ If yes, in what
way?
________________________________________________________________________
Speech
How many hours of speaking do you do in a day?
____________________________________
What is a typical day of communicating like for you?
__________________________________
________________________________________________________________________
_____
Do you pronounce your words clearly?
____________________________________________
Do people ask you to repeat yourself?
______________________________________________
Do people have a hard time understanding you?
______________________________________
What do you do when you want to be as easy to understand as possible?
__________________
________________________________________________________________________
_____
What percent of your speech do you think is understandable?
____________________________
Has your neurological diagnosis caused you to talk less?
________________________________
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If so, how much less? _____________

Why?

____________________________________
________________________________________________________________________
_____
Swallowing
Do you have any difficulty with swallowing? ___________________________________
Do you cough during mealtimes? _____________________
If yes, do you cough more with water or solid food?
_________________________________
Do you have difficulty making the food go down (need to swallow twice)?
____________
Does it take you longer to finish a meal than before your neurological diagnosis?
________________
Have you experienced any unintentional recent weight loss? _____________
Have you ever been diagnosed with pneumonia? ____________ If yes, when?
_____________
Have you changed your diet since your neurological diagnosis? ___________________
If yes, what did you modify? ___________________________________
Musculoskeletal system:
Has your doctor ever told you that you have: (circle all that apply)
•

Osteoarthritis or degenerative arthritis

•

Rheumatoid arthritis

•

Osteoporosis

•

Ankylosing Spondylitis

•

Unknown or other type of arthritis

•

Any other disease of joint or muscle:

•

Comments:
93

Cardiovascular system:
•

Has any family member had a heart attack prior to the age of 55?
o If so, how are they related to you?

•

Have you ever had frequent cramping in your legs while resting?
o If yes, is it a current problem?

•

_____________________________

Have you ever had pain or cramping in your legs while walking?
o If yes, is it a current problem?

________________________________

•

If yes, is this pain relieved by rest or by discontinuing walking?

•

Have you ever been told that you have high blood pressure
o If yes, what was the date of onset? ____________________
o Were you given any medications?

•

______________

Did a doctor ever tell you that you had a heart problem?
o If yes: What was the date of onset? _______________________

•

What did the doctor call it? _________________________________
o Were you given any medications?

____________________________

• Do you have any history of high cholesterol in your blood as evidenced by a
previous blood lipid tests?
________________________________________________________
Comments:

______________________

Endocrine system:
Have you ever had any of the following: Thyroid problems, adrenal problems,
diabetes mellitus?
•

________________________________________________________________

•

If yes to diabetes, which type?

Type 1 or Type 2

Date of onset- _________________________
Are/were you on any medication, or is it diet controlled?
_________________________
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Neurological system:
•

Do you have any significant problems with your memory? (circle all that apply)
o When answering the telephone, do you recall what you were doing
before it rang?
o Can you give the directions to your house/apartment?
o Can you keep appointments without a reminder?
o Can you remember what clothes you wore yesterday?

•

Any problems with vision other than corrective lens changes?
o If yes, which of the following conditions- Blindness, temporary loss
of vision, double vision, glaucoma, cataract, macular degeneration or
others.
____________________________________________________________
__

Do you have and of the following?: (circle all that apply)
•

Vertigo (a feeling of spinning, or unsteadiness)

•

Seizure or convulsions?

•

Migraine or severe headaches?

•

Paralysis of arm or leg?

•

A head injury with loss of consciousness?

•

Pain, numbness or tingling in your limbs?

•

Pain in your lower back?

•

Do you have pain in any part of body including headaches while exercising?

•

Have you been told that you have a peripheral neuropathy?

•

Tremors?

•

Problems with walking? If yes,
o Do you fall frequently?
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o Is your walking problem related to pain, weakness or loss of balance?
•

Have you ever had an operation on skull or brain?

•

Have you ever had meningitis or Brain fever?

Comments:
Previous Treatment
Have you had previous speech or swallow treatment, occupational therapy or physical
therapy? __________________________________________
If yes, please describe (when, what)
_______________________________________________
________________________________________________________________________
____
Was it beneficial?
_____________________________________________________________
If yes, what changes did you notice?
______________________________________________
________________________________________________________________________
____
Employment
Are you employed?
___________________________________________________________
Type of employment
__________________________________________________________
How much speaking do you do at your job?
___________________________________________
________________________________________________________________________
____
96

Other
Have you noticed any difficulty with your memory? _____________________________
Have you experienced any changes in your mood?
_______________________________
Is it difficult for you to pay attention long enough to finish a task?
___________________
Do you have any difficulty reading? ____________________________________
Do you have any difficulty writing? ___________________________________
Do you have any other health problems or conditions that would affect communication,
nutrition or physical activity?
________________________________________________________________________
_____
________________________________________________________________________
_____
Semi-Structured Interview Questions
Eating Environment:
1. Describe the most challenging aspects of preparing and eating meals since the
diagnosis of Parkinson’s disease.
2. Who is responsible for buying and preparing food in your home?
Dietary Intake:
1. How has your diet changed since being diagnosed with Parkinson’s disease?
Prompt: Are there any foods that you have stopped or increased eating due to
your diagnosis?
2. How would you describe your current diet? Prompt: Are you following any
special diet?
3. Who have you spoken with about your diet and what have they told you?
Prompt: What instructions have you been given and by whom?
4. Is there anything that you would like to know about the foods that you eat or
your daily nutrition in general? Probe: What questions or concerns about your
daily eating or about the foods you eat in general?
5. What is your understanding of a Protein Redistribution diet or a Low Protein
diet? Prompt: The Protein Redistribution diet limits protein during the day and
includes more protein at dinner; the Low Protein diet limits protein during the
day and at dinner.
6. What challenges would you anticipate if you were following a Protein
Redistribution or Low Protein diet?
7. What difficulties do you have chewing or swallowing your food or beverages?
Prompt: What fluids to you have difficulty consuming? How often do you
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cough during meals? How much more time does it take you to eat than before
the diagnosis?
8. Do you modify the textures or consistencies of your foods and beverages?
Prompt: Do you consume ground meat instead of whole pieces? Do you soften
or pureed your vegetables? Do you use products like “Simply Thick” to thicken
the fluids you consume?
Medication Management:
1. Describe your greatest challenges to taking your levodopa medication as
prescribed by your doctor?
2. How do you cope or overcome the challenges to taking you levodopa
medication as prescribed by your doctor?
3. What is your daily levodopa schedule?
4. What information have your doctor and pharmacist provided about the timing
of your medications?
5. How do you time your food and medication intakes?
6. How do you obtain information about your levodopa medication?
7. How well does levodopa manage your daily symptoms? Prompt: Do you ever
feel shaky, unsteady or sluggish after consuming your medication?
8. What do you know about food-drug interactions between levodopa and protein?
9. What information would you like to know about your medication management?
Probe: How interested are you in learning more?
10. Do you rely on your caregiver to receive your levodopa medication?
Final Questions
1. Is this anything else about maintaining a healthy diet that works with your
Parkinson medications that you want to share?
2. Is there anything else you would like to share regarding your journey with
Parkinson’s that you would like to share?

98

